ProQR begins Phase Ib trial of QR-010 to treat patients with cystic fibrosis

Dutch biotech firm ProQR Therapeutics has initiated a Phase Ib clinical trial (PQ-010-001) of QR-010, a new investigational RNA therapeutic designed to repair the genetic mutation in the mRNA of cystic fibrosis (CF) patients due to the DF508 mutation…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news